

- Pizarro D., Romero I., Pérez-Mies B., Redondo A., Caniego-Casas T., Carretero-Barrio I., Cristóbal E., Gutiérrez-Pecharromán A., Santaballa A., D'Angelo E., Hardisson D., Vieites B., Matías-Guiu X., Estévez P., Guerra E., Prat J., Poveda A., López-Guerrero J., and Palacios J., 2023, The prognostic significance of tumor-infiltrating lymphocytes, PD-L1, BRCA mutation status and tumor mutational burden in early-stage high-grade serous ovarian carcinoma-a study by the spanish group for ovarian cancer research (GEICO), *International Journal of Molecular Sciences*, 24(13): 11183.
<https://doi.org/10.3390/ijms241311183>
- Rached L., Laparra A., Sakkal M., Danlos F., Barlesi F., Carbonnel F., De Martin E., Ducreux M., Even C., Pavet L., Michot J., Ribeiro J.M., Scotté F., Aix S.P., Lambotte O., Baldini C., and Champiat S., 2024, Toxicity of immunotherapy combinations with chemotherapy across tumor indications: current knowledge and practical recommendations, *Cancer Treatment Reviews*, 127: 102751.
<https://doi.org/10.1016/j.ctrv.2024.102751>
- Rausch M., Bartels K., and Leibold J., 2025, Immunotherapy in ovarian cancer: spatial functional genomics to unravel resistance mechanisms, *Signal Transduction and Targeted Therapy*, 10(1): 17.
<https://doi.org/10.1038/s41392-024-02110-w>
- Rosario S.R., Long M.D., Chilakapati S., Gomez E.C., Battaglia S., Singh P., Wang J., Wang K., Attwood K., Hess S., McGray A., Odunsi K., Segal B., Paragh G., Liu S., Wargo J., and Zsiros E., 2024, Integrative multi-omics analysis uncovers tumor-immune-gut axis influencing immunotherapy outcomes in ovarian cancer, *Nature Communications*, 15(1): 10609.
<https://doi.org/10.1038/s41467-024-54565-8>
- Shahnam A., Hitchen N., Nindra U., Manoharan S., Desai J., Tran B., Solomon B., Luen S., Hui R., Hopkins A., and Sorich M., 2023, Objective response rate and progression-free survival as surrogates for overall survival treatment effect: a meta-analysis across diverse tumour groups and contemporary therapies, *European Journal of Cancer*, 198: 113503.
<https://doi.org/10.1016/j.ejca.2023.113503>
- Shawky M., Choudhary C., Coleridge S., Bryant A., and Morrison J., 2025, Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced epithelial ovarian cancer, *The Cochrane Database of Systematic Reviews*, 7: CD005343.
<https://doi.org/10.1002/14651858.cd005343.pub7>
- Shehaj I., Schröder M., Linz V., Krajnak S., Almstedt K., Stewen K., Schwab R., Hasenburg A., Schmidt M., and Heimes A., 2024, Occurrence and management of immunotherapy-associated adverse events in patients with gynecological cancers, *Cancers*, 16(7): 1371.
<https://doi.org/10.3390/cancers16071371>
- Tavares V., Marques I., De Melo I., Assis J., Pereira D., and Medeiros R., 2024, Paradigm shift: a comprehensive review of ovarian cancer management in an era of advancements, *International Journal of Molecular Sciences*, 25(3): 1845.
<https://doi.org/10.3390/ijms25031845>
- Vida R., Bartoletti M., Montico M., Rizzetto M., Zapelloni G., Corsetti S., Nicoloso M., Scalone S., Del Fabro A., Clemente N., Occhiali T., Lucia E., Reato C., Martella L., Caccin E., Poletto M., Tabaro G., Canzonieri V., Ditto A., and Puglisi F., 2025, Immunotherapy with anti-PD-1 or PD-L1 in advanced ovarian cancer (OC): a meta-analysis of randomized trials, *Cancer Treatment Reviews*, 144: 103094.
<https://doi.org/10.1016/j.ctrv.2026.103094>
- Wang G., Yang H., Wang Y., and Qin J., 2025, Ovarian cancer targeted therapy: current landscape and future challenges, *Frontiers in Oncology*, 15: 1535235.
<https://doi.org/10.3389/fonc.2025.1535235>
- Wang L., Zhang Q., Wang X., Dong Z., Liu S., Wang Q., Zhang Z., and Xing J., 2025, Therapeutic landscape of ovarian cancer: recent advances and emerging therapies, *Biomarker Research*, 13(1): 103.
<https://doi.org/10.1186/s40364-025-00818-7>
- Whipman J.M., Jacob F., Heinzelmann V., and Bodenmiller B., 2025, Abstract 5540: Deconstructing the lethality of recurrence in ovarian cancer through multi-modal spatiotemporal analysis, *Cancer Research*, 85(8_Supplement_1): 5540.
<https://doi.org/10.1158/1538-7445.am2025-5540>
- Zhang C., Yang J., Chen S., Sun L., Li K., Lai G., Peng B., Zhong X., and Xie B., 2024, Artificial intelligence in ovarian cancer drug resistance advanced 3PM approach: subtype classification and prognostic modeling, *EPMA Journal*, 15(3): 525-544.
<https://doi.org/10.1007/s13167-024-00374-4>

Disclaimer/Publisher's Note



The statements, opinions, and data contained in all publications are solely those of the individual authors and contributors and do not represent the views of the publishing house and/or its editors. The publisher and/or its editors disclaim all responsibility for any harm or damage to persons or property that may result from the application of ideas, methods, instructions, or products discussed in the content. Publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.